用年龄分层对质母细胞瘤患者的并发症和药理学分析
Erik E Rabin1, Jonathan Huang1, Miri Kim2
1Department of Neurological Surgery at Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Brain, behavior, & immunity - health
|April 11, 2024
概括
年龄会影响质母细胞瘤的预后,年轻患者表现较差,与移动性和心理健康问题有关. 老年患者面临着更糟糕的预后,但某些药物改善了两组患者的生存率.
科学领域:
- 神经瘤学神经瘤学
- 老年医学 老年医学
- 临床药理学 临床药理学
背景情况:
- 增加的年龄是质母细胞瘤 (GBM) 患者显著的负面预后因素.
- 患者年龄,并发症和药物对GBM存活率的相互作用仍未得到充分研究.
研究的目的:
- 研究伴随性疾病,症状和药物对GBM患者存活率的影响,按年龄分层.
- 确定未来研究和临床决策的潜在目标.
主要方法:
- 对565名IDHwt GBM患者的电子健康记录进行了回顾性分析.
- 数据按年龄 (65岁) 和MGMT促进剂甲基化状态分层.
- 采用了多变量时间依赖的Cox模型和队列内危险.
主要成果:
- 年轻的GBM患者 (<65岁) 的预后较差,有移动性问题和精神疾病.
- 较老的GBM患者 (≥65) 患的预后较差.
- 泰莫佐洛米德改善了两年龄组的生存率; ACE 抑制剂改善了老年患者的治疗结果.
结论:
- 在GBM患者中发现了临床因素和药物之间的新型年龄相关联系.
- 这些发现支持进一步研究特定年龄伴随性疾病和药物疗法,以进行个性化GBM治疗.
更多相关视频
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
7.9K
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
相关概念视频
Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863
